Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1976 1
1977 1
1980 1
1982 1
1983 1
1984 2
1985 3
1987 1
1988 3
1989 1
1990 3
1991 1
1992 4
1993 2
1994 2
1995 7
1996 4
1997 2
1998 2
1999 1
2000 3
2002 1
2003 1
2004 1
2005 1
2006 1
2007 2
2008 1
2011 3
2012 2
2013 3
2015 2
2016 2
2018 1
2019 1
2020 1
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

66 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Decreased lecithin cholesterol acyl transferase level"
Page 1
MEDI6012: Recombinant Human Lecithin Cholesterol Acyltransferase, High-Density Lipoprotein, and Low-Density Lipoprotein Receptor-Mediated Reverse Cholesterol Transport.
George RT, Abuhatzira L, Stoughton SM, Karathanasis SK, She D, Jin C, Buss NAPS, Bakker-Arkema R, Ongstad EL, Koren M, Hirshberg B. George RT, et al. J Am Heart Assoc. 2021 Jul 6;10(13):e014572. doi: 10.1161/JAHA.119.014572. Epub 2021 Jun 14. J Am Heart Assoc. 2021. PMID: 34121413 Free PMC article. Clinical Trial.
Background MEDI6012 is recombinant human lecithin cholesterol acyltransferase, the rate-limiting enzyme in reverse cholesterol transport. Infusions of lecithin cholesterol acyltransferase have the potential to enhance reverse cholesterol …
Background MEDI6012 is recombinant human lecithin cholesterol acyltransferase, the rate-limiting enzyme in reverse choleste …
Danazol and plasma lipoprotein metabolism.
Shepherd J. Shepherd J. Int J Gynaecol Obstet. 1995 Sep;50 Suppl 1:S23-6. doi: 10.1016/0020-7292(95)02511-a. Int J Gynaecol Obstet. 1995. PMID: 8529771 Review.
Danazol may exert a regulatory influence on three key processes in lipoprotein metabolism: hepatic lipase activity; low-density lipoprotein receptor function; and lecithin:cholesterol acyl-transferase activity. Danazol decreases plasma fibrinoge …
Danazol may exert a regulatory influence on three key processes in lipoprotein metabolism: hepatic lipase activity; low-density lipoprotein …
Hyperlipidemia of chronic renal failure.
Kaysen GA. Kaysen GA. Blood Purif. 1994;12(1):60-7. doi: 10.1159/000170146. Blood Purif. 1994. PMID: 7986478 Review.
Lecithin:cholesterol acyltransferase (LCAT), an enzyme necessary for HDL maturation, is reduced in chronic renal failure (CRF). ...Triglycerides decrease and cholesterol increases following transplantation. Oxidized lipids are increased in plasma of pa …
Lecithin:cholesterol acyltransferase (LCAT), an enzyme necessary for HDL maturation, is reduced in chronic renal failure (CRF) …
Changes in lecithin: cholesterol acyltransferase, cholesteryl ester transfer protein and paraoxonase-1 activities in patients with colorectal cancer.
Mihajlovic M, Gojkovic T, Vladimirov S, Miljkovic M, Stefanovic A, Vekic J, Zeljkovic D, Trifunovic B, Kotur-Stevuljevic J, Spasojevic-Kalimanovska V, Zeljkovic A. Mihajlovic M, et al. Clin Biochem. 2019 Jan;63:32-38. doi: 10.1016/j.clinbiochem.2018.11.010. Epub 2018 Nov 28. Clin Biochem. 2019. PMID: 30500525 Clinical Trial.
BACKGROUND: Previous studies revealed decreased level of high-density lipoprotein cholesterol (HDLC) as important factor for development of colorectal cancer (CRC). Quantity and structure of HDL particles depend on activities of lipid transfer proteins lec …
BACKGROUND: Previous studies revealed decreased level of high-density lipoprotein cholesterol (HDLC) as important facto …
Simvastatin and bezafibrate: effects on serum lipoproteins and lecithin: cholesterol acyltransferase activity in familial hypercholesterolaemia.
Weisweiler P. Weisweiler P. Eur J Clin Pharmacol. 1988;35(6):579-83. doi: 10.1007/BF00637592. Eur J Clin Pharmacol. 1988. PMID: 3234467 Clinical Trial.
Both drugs produced significant reductions in serum and LDL cholesterol; mean percentage fall -30.5% and -38.1% (simvastatin) and -17.8% and -20.6% (bezafibrate), respectively. Both drugs also caused a decrease in VLDL cholesterol, while only bezafibrate d …
Both drugs produced significant reductions in serum and LDL cholesterol; mean percentage fall -30.5% and -38.1% (simvastatin) and -17 …
Familial lecithin:cholesterol acyltransferase deficiency: First-in-human treatment with enzyme replacement.
Shamburek RD, Bakker-Arkema R, Auerbach BJ, Krause BR, Homan R, Amar MJ, Freeman LA, Remaley AT. Shamburek RD, et al. J Clin Lipidol. 2016 Mar-Apr;10(2):356-67. doi: 10.1016/j.jacl.2015.12.007. Epub 2015 Dec 23. J Clin Lipidol. 2016. PMID: 27055967 Free PMC article.
BACKGROUND: Humans with familial lecithin:cholesterol acyltransferase (LCAT) deficiency (FLD) have extremely low or undetectable high-density lipoprotein cholesterol (HDL-C) levels and by early adulthood develop many manifestations of the disorder, inc …
BACKGROUND: Humans with familial lecithin:cholesterol acyltransferase (LCAT) deficiency (FLD) have extremely low or undetectab …
Decreased plasma cholesterol esterification and cholesteryl ester transfer in hypopituitary patients on glucocorticoid replacement therapy.
Beentjes JA, van Tol A, Sluiter WJ, Dullaart RP. Beentjes JA, et al. Scand J Clin Lab Invest. 2000 May;60(3):189-98. doi: 10.1080/003655100750044839. Scand J Clin Lab Invest. 2000. PMID: 10885490
No data are available with respect to the effect of glucocorticoid replacement therapy on high density lipoproteins (HDL) metabolism in such patients. Plasma lecithin:cholesterol acyl transferase (LCAT), cholesteryl ester transfer protein (CETP) and ph …
No data are available with respect to the effect of glucocorticoid replacement therapy on high density lipoproteins (HDL) metabolism in such …
Lipoprotein pattern and plasma lecithin cholesterol acyl transferase activity in children with Alagille syndrome.
Gottrand F, Clavey V, Fruchart JC, Farriaux JP. Gottrand F, et al. Atherosclerosis. 1995 Jun;115(2):233-41. doi: 10.1016/0021-9150(94)05521-j. Atherosclerosis. 1995. PMID: 7661882 Clinical Trial.
The aim of the study was to assess the lipid profile (plasma lipoproteins, apolipoproteins (apo)) and lecithin cholesterol acyl transferase (LCAT) activity, with and without treatment with cholestyramine in Alagille syndrome. ...Some of the risk factor …
The aim of the study was to assess the lipid profile (plasma lipoproteins, apolipoproteins (apo)) and lecithin cholesterol …
The effect of atorvastatin therapy on lecithin:cholesterol acyltransferase, cholesteryl ester transfer protein and the antioxidant paraoxonase.
Kassai A, Illyés L, Mirdamadi HZ, Seres I, Kalmár T, Audikovszky M, Paragh G. Kassai A, et al. Clin Biochem. 2007 Jan;40(1-2):1-5. doi: 10.1016/j.clinbiochem.2006.05.016. Epub 2006 Jun 9. Clin Biochem. 2007. PMID: 16999950 Clinical Trial.
We measured the serum paraoxonase activity and concentration, oxidized LDL, LCAT and CETP activities. RESULTS: Atorvastatin significantly reduced the levels of cholesterol, triglyceride, LDL-C and apoB, while it did not influence the levels of HDL-C and apo A …
We measured the serum paraoxonase activity and concentration, oxidized LDL, LCAT and CETP activities. RESULTS: Atorvastatin significantly re …
LCAT, HDL cholesterol and ischemic cardiovascular disease: a Mendelian randomization study of HDL cholesterol in 54,500 individuals.
Haase CL, Tybjærg-Hansen A, Qayyum AA, Schou J, Nordestgaard BG, Frikke-Schmidt R. Haase CL, et al. J Clin Endocrinol Metab. 2012 Feb;97(2):E248-56. doi: 10.1210/jc.2011-1846. Epub 2011 Nov 16. J Clin Endocrinol Metab. 2012. PMID: 22090275
S208T associated with a 13% (0.21 mmol/liter) decrease in HDL cholesterol levels but not with increased risk of MI or other ischemic end points. ...CONCLUSION: Low plasma HDL cholesterol levels robustly associated with increased risk of MI but g …
S208T associated with a 13% (0.21 mmol/liter) decrease in HDL cholesterol levels but not with increased risk of MI or o …
66 results